Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.61 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | FURIN | P09958 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | CIB1 | Q99828 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805444 | 0.87 | ELANE (0.57) | ELANEST14EPHA2PLG | |
| SCHEMBL29805416 | 0.87 | ELANE (0.53) | ELANEST14EPHA2PLGFURIN | |
| SCHEMBL29805574 | 0.82 | ELANE (0.52) | ELANEST14EPHA2 | |
| SCHEMBL29865959 | 0.81 | SLC6A3 (0.52) | ELANEST14PLGKLK5ALB | |
| SCHEMBL29390244 | 0.81 | SLC6A3 (0.52) | ELANEST14PLGKLK5ALB | |
| Cyclopsychotride A SCHEMBL30116118 | 0.81 | ELANE (0.61) | ELANEST14EPHA2PLGSLC6A3 | |
| SCHEMBL29805506 | 0.81 | ELANE (0.53) | ELANEST14EPHA2 | |
| SCHEMBL29885347 | 0.80 | PLG (0.53) | ELANEST14EPHA2PLGFURIN | |
| SCHEMBL29805481 | 0.80 | F11 (0.49) | ELANEST14FURIN | |
| SCHEMBL16576429 | 0.79 | HDAC4 (0.53) | PLGKLK5ALBHDAC4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| CN-120060460-A | Application of extracellular trapping net in preventing and inhibiting myopia development | 复旦大学附属中山医院 | 2025-05-30 | — | — | CN | claimed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | claimed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | claimed |
| US-20240148765-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-05-09 | — | — | US | claimed |
| US-20230127290-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | US | claimed |
| WO-2022192796-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING THERAPY-RELATED CARDIOMYOPATHY ASSOCIATED WITH NEUTROPHIL INFILTRATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-09-15 | — | — | WO | claimed |
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137696-A1 | Compositions Comprising an Inhibitor of Galectin-3 | UNIVERSITY OF LIVERPOOL (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739296-A1 | COMPOSITIONS COMPRISING AN INHIBITOR OF GALECTIN-3 | University of Liverpool (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4017497-A1 | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE | pH Pharma Co., Ltd. (KR) | 2022-06-29 | — | — | EP | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | ELANE 192/4885ST14 4247/4885EPHA2 699/4885 |
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | ELANE 509/4885ST14 3399/4885EPHA2 3690/4885 |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | ELANE 2/4885ST14 1726/4885EPHA2 3210/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | ELANE 472/4885ST14 2567/4885EPHA2 4245/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | ELANE 307/4885ST14 3337/4885EPHA2 3528/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | ELANE 530/4885ST14 2533/4885EPHA2 3577/4885 |
| US-20260137696-A1 | Compositions Comprising an Inhibitor of Galectin-3 | LGALS3, LGALS1, LGALS2 | ELANE 249/4885ST14 157/4885EPHA2 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.